These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

189 related items for PubMed ID: 18931571

  • 1. [Phase I study of CPT-11 and continuous 5-FU / l-leucovorin combination therapy(modified AIO regimen)in patients with metastatic colorectal cancer].
    Nakamura T, Kurachi K, Fukazawa A, Hayashi T, Nakamura K, Nakajima A, Suzuki S, Konno H.
    Gan To Kagaku Ryoho; 2008 Oct; 35(10):1697-701. PubMed ID: 18931571
    [Abstract] [Full Text] [Related]

  • 2. Phase I/II study of irinotecan, 5-fluorouracil, and l-leucovorin combination therapy (modified Saltz regimen) in patients with metastatic colorectal cancer.
    Goto A, Yamada Y, Hosokawa A, Ura T, Arai T, Hamaguchi T, Muro K, Shimada Y, Shirao K.
    Int J Clin Oncol; 2004 Oct; 9(5):364-8. PubMed ID: 15549585
    [Abstract] [Full Text] [Related]

  • 3. Phase I study of CPT-11 and bolus 5-FU/ l-leucovorin in patients with metastatic colorectal cancer.
    Fujishima H, Kikuchi I, Miyanaga O, Ueda A, Baba E, Mitsugi K, Harada M, Nakano S.
    Int J Clin Oncol; 2004 Apr; 9(2):92-7. PubMed ID: 15108040
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Gefitinib in combination with 5-fluorouracil (5-FU)/folinic acid and irinotecan in patients with 5-FU/oxaliplatin- refractory colorectal cancer: a phase I/II study of the Arbeitsgemeinschaft für Internistische Onkologie (AIO).
    Hofheinz RD, Kubicka S, Wollert J, Arnold D, Hochhaus A.
    Onkologie; 2006 Dec; 29(12):563-7. PubMed ID: 17202826
    [Abstract] [Full Text] [Related]

  • 9. Phase I study of a weekly schedule of irinotecan, high-dose leucovorin, and infusional fluorouracil as first-line chemotherapy in patients with advanced colorectal cancer.
    Vanhoefer U, Harstrick A, Köhne CH, Achterrath W, Rustum YM, Seeber S, Wilke H.
    J Clin Oncol; 1999 Mar; 17(3):907-13. PubMed ID: 10071283
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Phase I and pharmacokinetic study of two different schedules of oxaliplatin, irinotecan, Fluorouracil, and leucovorin in patients with solid tumors.
    Goetz MP, Erlichman C, Windebank AJ, Reid JM, Sloan JA, Atherton P, Adjei AA, Rubin J, Pitot H, Galanis E, Ames MM, Goldberg RM.
    J Clin Oncol; 2003 Oct 15; 21(20):3761-9. PubMed ID: 12963697
    [Abstract] [Full Text] [Related]

  • 12. Multiple-target chemotherapy (LV-modulated 5-FU bolus and continuous infusion, oxaliplatin, CPT- 11) in advanced 5-FU-refractory colorectal cancer: MTD definition and efficacy evaluation. A phase I-II study.
    Bonetti A, Zaninelli M, Durante E, Fraccon AP, Franceschi T, Pasini F, Zustovich F, Brienza S.
    Tumori; 2006 Oct 15; 92(5):389-95. PubMed ID: 17168430
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Palliative second-line treatment with weekly high-dose 5-fluorouracil as 24-hour infusion and folinic acid (AIO) plus oxaliplatin after pre-treatment with the AIO-regimen in colorectal cancer (CRC).
    Link K, Happich K, Schirner I, Jüngert B, Brückl V, Männlein G, Brückl WM, Merkel S, Göhl J, Hohenberger W, Hahn EG, Wein A.
    Anticancer Res; 2004 Oct 15; 24(1):385-91. PubMed ID: 15015625
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Efficacy and toxicity of fluorouracil, leucovorin plus oxaliplatin (FOLFOX4 and modified FOLFOX6) followed by fluorouracil, leucovorin plus irinotecan(FOLFIRI)for advanced or metastatic colorectal cancer--case studies.
    Ohtani H, Arimoto Y, Nishio K, Kanamiya Y, Oba H, Adachi K, Shintani M, Nakamura R, Yui S.
    Gan To Kagaku Ryoho; 2008 Oct 15; 35(10):1769-74. PubMed ID: 18931586
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.